The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later

Abstract

In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC; www.cpicpgx.org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB, http:// www.pharmgkb.org) and the National Institutes of Health (NIH), was created to provide freely available, evidence-based, peer-reviewed, and updated pharmacogenetic clinical practice guidelines. To date, CPIC has published 23 guidelines (of which 11 have been updated), covering 19 genes and 46 drugs across several therapeutic areas. CPIC also now provides additional resources to facilitate the implementation of pharmacogenetics into routine clinical practice and the electronic health record. Furthermore, since its inception, CPIC's interactions with other resources, databases, websites and genomic communities have grown. This purpose of this paper is to highlight the progress of CPIC over the past 10 years.

Knowledge and attitudes on pharmacogenetics among pediatricians

“…A commonly cited challenge by providers and medical centers when considering clinical pharmacogenetic testing is a need for professional practice guidelines [7,[19][20][21]. In an effort to address this vital component, the CPIC was formed in 2009 to develop and disseminate evidence-based guidelines for pharmacogenetic-guided therapy without any formal recommendation for or against testing [9,10]. These published guidelines typically are centered around specific gene-drug pairs, and to date are publicly available for 19 genes and >45 medications.…”

“…However, evidence-based pharmacogenetic practice guidelines have recently been developed and disseminated for selected gene-drug pairs by the Clinical Pharmacogenetics Implementation Consortium (CPIC; https://cpicpgx. org/guidelines/) [9,10], which increasingly include specific recommendations for pediatric patients. The availability of CPIC guidelines and the growing number of federally funded clinical research programs dedicated to newborn genome sequencing [11,12] together indicate that physicians, including pediatricians, will increasingly be exposed to pharmacogenetic and other genetic risk factor results.…”

Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance

“…SNPs also contribute to an individual's pharmacogenomic profile, and thus influence overall drug effectiveness, therapeutic index, adverse drug reactions, and other kinetic processes [9][10][11]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has reported approximately 350 drug-gene pairs (110 of which are identified as actionable pairs (this indicates the SNP requires altered drug selection or dosing)); however antihypertensive drug-gene pairs have not been endorsed yet [11,12]. Similarly, the Dutch Pharmacogenomic Working Group (DPWG) has recommended only one actionable antihypertensive drug-gene pair (i.e., CYP2D6 and metoprolol) [13].…”

Rational Use of Drugs: the Value of Clinical Pharmacology

“…Найбільш близька до клінічної практики в даний час фармакогеномікаширокий напрямок, що передбачає вивчення генетичних відмінностей на рівні цілого генома, а не тільки генів, які беруть участь в транспорті та метаболізмі лікарських засобів. Завдання, що стоїть перед цим напрямком, одневиявлення груп пацієнтів, для яких «стандартна» доза препарату є неприйнятною, в зв'язку з генетичними особливостями, що торкаються фармакокінетичних та фармакодинамічних процесів [1,2,[9][10][11].…”